|
Nov 30
|
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
|
|
Jun 27
|
Bavarian Nordic Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine Candidate
|
|
Jun 23
|
Bavarian Nordic to Supply Smallpox Vaccines for EU Strategic Reserve
|
|
Jun 20
|
Bavarian Nordic Reports Data from a Phase 3 Clinical Trial of its VLP-Based Chikungunya Virus Vaccine in Adults ≥65 Years of Age
|
|
Jun 16
|
Bavarian Nordic Reports 12-Month Durability Data from a Phase 2 Clinical Trial of its COVID-19 Vaccine Candidate
|
|
Apr 25
|
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
|